Catabasis shares 1st triglyceride data for drug conjugate
This article was originally published in Scrip
Preliminary data from a Phase I clinical trial for the Catabasis Pharmaceuticals hypertriglyceridemia drug CAT-2003 show significant reductions in fasting and post-prandial triglyceride levels in both healthy volunteers and patients with mild lipid elevations.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.